Akero Therapeutics, Inc. (NASDAQ:AKRO) CFO Sells $89,608.56 in Stock

Akero Therapeutics, Inc. (NASDAQ:AKRO - Get Free Report) CFO William Richard White sold 1,634 shares of the stock in a transaction dated Wednesday, June 18th. The stock was sold at an average price of $54.84, for a total transaction of $89,608.56. Following the sale, the chief financial officer now owns 57,521 shares in the company, valued at $3,154,451.64. The trade was a 2.76% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website.

William Richard White also recently made the following trade(s):

• On Tuesday, June 10th, William Richard White sold 2,804 shares of Akero Therapeutics stock. The stock was sold at an average price of $53.99, for a total value of $151,387.96.

Akero Therapeutics Stock Performance

Shares of AKRO stock traded down $0.17 on Monday, reaching $54.03. The stock had a trading volume of 1,271,985 shares, compared to its average volume of 1,014,119. Akero Therapeutics, Inc. has a 1 year low of $21.02 and a 1 year high of $58.40. The stock has a market cap of $4.31 billion, a P/E ratio of -27.71 and a beta of -0.16. The company has a debt-to-equity ratio of 0.03, a quick ratio of 16.80 and a current ratio of 16.80. The company has a 50 day simple moving average of $45.88 and a 200 day simple moving average of $41.25.

Akero Therapeutics (NASDAQ:AKRO - Get Free Report) last released its earnings results on Monday, May 12th. The company reported $0.90 EPS for the quarter, topping the consensus estimate of ($1.01) by $1.91. Equities research analysts expect that Akero Therapeutics, Inc. will post -3.99 EPS for the current year.

Wall Street Analyst Weigh In

AKRO has been the topic of a number of research reports. Citigroup dropped their price target on Akero Therapeutics from $80.00 to $78.00 and set a "buy" rating on the stock in a research note on Tuesday, May 13th. Bank of America upped their price objective on shares of Akero Therapeutics from $63.00 to $64.00 and gave the stock a "buy" rating in a research report on Tuesday, May 27th. Morgan Stanley reissued an "overweight" rating on shares of Akero Therapeutics in a report on Sunday, March 2nd. Finally, HC Wainwright raised their target price on Akero Therapeutics from $72.00 to $75.00 and gave the stock a "buy" rating in a research report on Monday, March 3rd. Six investment analysts have rated the stock with a buy rating, According to MarketBeat.com, Akero Therapeutics presently has a consensus rating of "Buy" and an average target price of $82.50.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the company. Northwest & Ethical Investments L.P. purchased a new position in Akero Therapeutics during the first quarter valued at $32,000. GF Fund Management CO. LTD. purchased a new stake in shares of Akero Therapeutics in the 4th quarter valued at approximately $41,000. Sterling Capital Management LLC raised its position in shares of Akero Therapeutics by 764.3% during the 4th quarter. Sterling Capital Management LLC now owns 1,789 shares of the company's stock worth $50,000 after acquiring an additional 1,582 shares in the last quarter. PNC Financial Services Group Inc. grew its holdings in shares of Akero Therapeutics by 30.8% during the first quarter. PNC Financial Services Group Inc. now owns 1,658 shares of the company's stock worth $67,000 after purchasing an additional 390 shares during the last quarter. Finally, Quarry LP acquired a new position in shares of Akero Therapeutics in the 4th quarter valued at $83,000.

Akero Therapeutics Company Profile

Akero Therapeutics, Inc, together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), which is in Phase 3 clinical trials that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients.